Investor Information
Financial Overview
As at August 28, 2020 there were 121,086,516 common shares issued and outstanding.
Stock Options
At August 28, 2020 the following common share purchase options were outstanding:
| Expiry Date |
Number Outstanding |
Exercise Price |
Number Exercisable (Vested) |
| May 4, 2021 |
1,355,000 |
0.05 |
1,355,000 |
| June 28, 2018 |
75,000 |
0.10 |
75,000 |
| January 9, 2022 |
2,250,000 |
0.17 |
2,250,000 |
| February 26, 2023 |
2,100,000 |
0.15 |
2,100,000 |
| September 4, 2024 |
1,530,000 |
0.07 |
510,000 |
| |
7,310,000 |
0.10 |
6,290,000 |
Share purchase warrants
As at August 28, 2020 there were no share purchase warrants outstanding.
Financial Statements
| Fiscal Year 2020 |
| 2nd Quarter Report for the period ended June 30, 2020 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2020 |
FS |
MD&A |
| Fiscal Year 2019 |
| Audited Annual Financial Statements for the year ended December 31, 2019 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2019 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2019 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2019 |
FS |
MD&A |
| Fiscal Year 2018 |
| Audited Annual Financial Statements for the year ended December 31, 2018 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2018 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2018 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2018 |
FS |
MD&A |
| Fiscal Year 2017 |
| Audited Annual Financial Statements for the year ended December 31, 2017 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2017 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2017 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2017 |
FS |
MD&A |
| Fiscal Year 2016 |
| Audited Annual Financial Statements for the year ended December 31, 2016 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2016 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2016 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2016 |
FS |
MD&A |
| Fiscal Year 2015 |
| Audited Annual Financial Statements for the year ended December 31, 2015 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2015 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2015 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2015 |
FS |
MD&A |
| Fiscal Year 2014 |
| Audited Annual Financial Statements for the year ended December 31, 2014 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2014 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2014 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2014 |
FS |
MD&A |
| Fiscal Year 2013 |
| Audited Annual Financial Statements for the year ended December 31, 2013 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2013 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2013 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2013 |
FS |
MD&A |
| Fiscal Year 2012 |
| Audited Annual Financial Statements for the year ended December 31, 2012 |
FS |
MD&A |
| 3rd Quarter Report for the period ended September 30, 2012 |
FS |
MD&A |
| 2nd Quarter Report for the period ended June 30, 2012 |
FS |
MD&A |
| 1st Quarter Report for the period ended March 31, 2012 |
FS |
MD&A |
| Fiscal Year 2011 |
| Audited Annual Financial Statements for the year ended December 31, 2011 |
FS |
MD&A |
Contact Investor Information